LumiThera

23 articles with LumiThera

• LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edema

  5/7/2021

  LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular damage and diseases, today announced research investigators lead by Drs. Hakan Kaymak, Inken Becker and Hartmut Schwahn, from the  Macula Retina Centre of Breyer Kaymak & Klabe Eye Clinic in Dusseldorf, Germany

• LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration

  4/7/2021

  LumiThera Inc., a commercial stage medical device company delivering photobiomodulation treatment for ocular disorders and disease, announced positive findings in its LIGHTSITE II, multi-center clinical trial in dry Age-Related Macular Degeneration patients.

• LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD patients

  2/16/2021

   LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. 

• LumiThera Completes Patient Enrollment in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration

  2/10/2021

  LumiThera, Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed enrollment in its multi-center United States clinical study in non-neovascular (dry) Age-Related Macular Degeneration (AMD) patients.

• LumiThera Announces Ryan Montecucco as General Counsel

  11/12/2020

   LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Ryan Montecucco as General Counsel and Secretary.  "We are very pleased to have Ryan join our team," stated Clark Tedford , Ph.D., President and CEO. "Ryan has been

• LumiThera Receives Notice of Award for $1.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Diabetic Retinopathy and Macular Edema

  9/3/2020

   LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI).

• LumiThera Closes Series C Round of Financing

  7/8/2020

   LumiThera Inc., a commercial stage private medical device company, creating a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed its Series C financing.  The company raised approximately $14M to support further commercialization of its Valeda Light Delivery System for the

• LumiThera to Expand Research into Diabetic Retinopathy for Valeda® Light Delivery System

  2/18/2020

  LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in Diabetic Retinopathy (DR). 

• LumiThera Adds Daniel Bertholet to Board of Directors

  1/23/2020

  LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Daniel Bertholet to the Board of Directors. 

• LumiThera Closes 2nd Tranche of Series C Financing

  1/13/2020

  LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has closed the 2nd tranche of its Series C round of financing.

• LumiThera Enrolls First Patient in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration

  10/1/2019

  LumiThera Inc. announced it has begun enrolling patients in a multi-center United States clinical study in dry Age-Related Macular Degeneration patients.

• Valeda Light Delivery System Receives 2019 Medical Design Excellence Award

  6/12/2019

  LumiThera and Product Creation Studio Honored for Product Design

• LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration

  4/11/2019

  LumiThera Inc. announced it has begun enrolling patients in a European Union multi-center clinical study in dry Age-Related Macular Degeneration patients.

• LumiThera Receives Seattle Business Magazine 2019 Leaders in Health Care Award for Achievement in Medical Technology

  3/12/2019

  The Leaders in Health Care Awards is considered to be one of the Pacific Northwest's most distinguished health care awards events of the year.

• LumiThera Announces an Agreement with Andrec Corporation S.A. to Distribute the Valeda Light Delivery System in Colombia and Several Latin American Countries

  3/7/2019

  LumiThera Inc. announced an agreement with Andrec Corporation S.A. to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Colombia and several Latin America countries.

• LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration

  2/26/2019

  The phase II grant supports a prospective, randomized, multi-center human clinical trial in U.S. subjects diagnosed with dry age-related macular degeneration

• LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy

  12/11/2018

  LumiThera, Inc., announced a distribution agreement with Miloftalmica to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Italy.

• LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe

  10/24/2018

  Optos is recognized as the leading provider of ultra-widefield retinal imaging devices to eyecare professionals for improved patient eye care.

• LumiThera, Inc. Selected to Present at the Ophthalmology Innovation Summit 2018 at the American Academy of Ophthalmology, Chicago, IL

  10/19/2018

  LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting on October 25, 2018, in Chicago, IL.

• LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark

  6/22/2018

  The "CE" mark is the abbreviation for Conformité Européenne, meaning European Conformity.